| [1] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57(1):167-185.
|
| [2] |
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
|
| [3] |
中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 中华肝脏病杂志,2015,23(12):888-905.
|
| [4] |
Martin P, Lau DTY, Nguyen MH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update[J]. Clin Hepatol Gas,2015,13(12):2071-2087(e16).
|
| [5] |
Wang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response[J]. World J Gastroenterol,2014,20(23):7207-7212.
|
| [6] |
Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus[J]. Expert Rev Gas,2009,3(5):499-512.
|
| [7] |
Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(1):100-107.
|
| [8] |
Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med,2004,116(12):829-834.
|
| [9] |
Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol,2007,46(1):45-52.
|
| [10] |
Sarri G, Westby M, Bermingham S, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance[J]. BMJ,2013,347(7915):31-33.
|
| [11] |
Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection[J]. J Hepatol,2010,52(6):791-799.
|
| [12] |
Güzelbulut F, Ovünç AO, Oetinkaya ZA, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B[J]. Hepato Gastroenterology,2012,59(114):477-480.
|
| [13] |
Sonneveld MJ, Zoutendijk R, Hansen BE, et al. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir[J]. Antivir Ther,2012,17(8):1605-1608.
|
| [14] |
Mao Q, Zhang HY, You JP, et al. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid[J]. Virol J,2012,9:136.
|
| [15] |
Seto WK, Hui AJ, Wong VWS, et al. Original article:treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study[J]. Gut,2015,64(4):667-672.
|
| [16] |
Chi H, Hansen BE, Yim C, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B[J]. Aliment Pharmacol Ther,2015,41(9):867-876.
|
| [17] |
Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int,2013,7(1):88-97.
|
| [18] |
Buster EHCJ, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b[J]. Gastroenterology,2008,135(2): 459-467.
|
| [19] |
Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy[J]. Antivir Ther,2011,16(5):629-637.
|
| [20] |
Strassburg CP. What is the influence of genotype on the success of treatment for chronic hepatitis B? Nature clinical practice[J]. Gastroen Hepatol,2006,3(11):620-621.
|
| [21] |
Mao QG, Pan JS, Fang KN, et al. Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha[J]. World J Gastroenterol,2010,16(27):3465-3471.
|
| [22] |
Carlo F. HBV and the immune response[J]. Liver Int,2015,35(1):121-128.
|
| [23] |
Reignat S, Webster GJM, Brown D, et al. Escaping high viral load exhaustion[J]. J Exp Med,2002,195(9):1089-1101.
|
| [24] |
Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues[J]. Gastroenterology,2012,143(4):963-973(e9).
|
| [25] |
Boglione L, D’Avolio A, Cariti G, et al. Sequential therapy with entecavir and PegINF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes[J]. Viral Hepat,2013,20(4):11-19.
|
| [26] |
Okuse C, Yotsuyanagi H, Yamada N, et al. Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B[J]. Hepatol Res,2010,40(5):461-469.
|
| [27] |
Piccolo P, Lenci I, Paolo D, et al. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B[J]. Antivir Ther,2013,18(1):57-64.
|
| [28] |
Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients[J]. Am J Gastroenterol,2005,100(11):2463-2471.
|
| [29] |
Annikki N, Femke S, Louis J, et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy[J]. J Hepatol,2016,64(3):539-546.
|
| [30] |
Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. New Engl J Med,2005,352(26):2682-2695.
|
| [31] |
Marcellin P, Lau KKG, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-Negative chronic hepatitis B[J]. New Engl J Med,2004,351(12):1206-1217.
|
| [32] |
Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group[J]. New Engl J Med,1998,339(2):61-68.
|
| [33] |
Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase[J]. Gut,2003,52(3):420-424.
|
| [34] |
Eric H, Buster CJ, Hansen BE, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J]. Gastroenterology,2009,137(6):2002-2009.
|
| [35] |
Boglione, Cariti G, Di PG, et al. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B[J]. J Med Virol,2016,88(11):1953-1959.
|
| [36] |
Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol,2014,61(4):777-784.
|
| [37] |
Caruntu FA, Curescu M, Olaru I, et al. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study[J]. Gastrointestin Liver Dis,2013,22(1):27-32.
|
| [38] |
Peng H, Wei F, Liu JY, et al. Response-guided therapy of regimens based on Peg-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis[J]. Hepatol Int,2015,9(4):543-557.
|
| [39] |
Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients[J]. J Viral Hepatitis,2011,18(8):580-586.
|
| [40] |
Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment[J]. Antimicrob Agents Chemother,2015,59(7):4121-4128.
|
| [41] |
Matsumoto A, Yatsuhashi H, Nagaoka S, et al. Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B[J]. Hepatol Res,2015,45(12):1195-1202.
|
| [42] |
Suzuki F, Arase Y, Suzuki Y, et al. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan[J]. J Gastroenterology,2012,47(7):814-822.
|
| [43] |
Michelle MP, Tarik A, Patrick M. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients[J]. Liver Int,2015,35(1):82-90.
|
| [44] |
纪永健，李菲菲，任万华, 等. HBeAg早期下降对聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的疗效预测[J]. 中华肝脏病杂志,2013,21(5):335-339.
|
| [45] |
Chen GY, Zhu MF, Zheng DL, et al. Baseline HBsAg predicts response to pegylated interferon-α-2b in HBeAg-positive chronic hepatitis B patients[J]. World J Gastroenterol,2014,20(25):8195-8200.
|
| [46] |
Milan JS, Vincent R, Charles ABB, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J]. Hepatology,2010,52(4):1251-1257.
|
| [47] |
Fan R, Sun J, Yuan Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleoside analogues[J]. Gut,2016,65(2):313-320.
|
| [48] |
于海滨，玛丽娜，柳雅立, 等. 非活动性HBsAg携带者聚乙二醇干扰素α-2a治疗过程中CD8+38+/CD8+变化及其临床意义[J]. 中华肝脏病杂志,2013,21(12):895-898.
|